Jump to Navigation

A January 2007 report in The New England Journal of Medicine stated that the hyperprolactinemia medication Dostinex (cabergoline) is significantly associated with cardiac valve disease. The study found that 29 percent of the patients taking Dostinex have damaged heart valves. Only 6 percent of the control subjects (who were not taking the drug) suffered from this. Pfizer Inc., the maker of the drug, identifies the mild warning of this significant risk as only a "precaution."

Dostinex is used to treat excess secretion of the hormone prolactin in a disorder known as hyperprolactinemia. It is also used to treat Parkinson's disease in Europe, but was approved by the FDA in 1996 only for the treatment of hyperprolactinemia.

In December 2006, Pfizer had added a precautionary warning to Dostinex labels, a minor change that would not be obvious to prescribing doctors but that did identify the potential for cardiac damage. If you have suffered any heart problems and have used Dostinex, please obtain a Free Consultation by submitting our online form, or by calling 866-273-1941.

OFFICE LOCATION: 707 Grant Street, Suite 2500 | Pittsburgh, PA 15219 | Phone: 866-273-1941 | Fax: 412-281-4229 | Email Us | Get Directions